News Earendil raises $787m as lead TL1A antibody starts phase 2 Earendil has raised an impressive $787m in financing for its AI-powered drug platform, attracting yet more buy-in from Sanofi.
News Novartis snaps up PI3Kα breast cancer drug in $3bn deal Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.
News Kidney biotech R1's $78m debut, and other biofinancings Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.
News Lilly's triple agonist retatrutide passes diabetes test Eli Lilly has positive phase 3 results for its triple agonist retatrutide in diabetes to go with its earlier encouraging data in obesity.
News Generic semaglutide in India, and other weight-loss news Novo Nordisk is facing generic semaglutide in India, Atrogi is testing a new weight loss approach, and Structure has more data with its oral GLP-1.
News Basecamp lifts veil on Trillion Gene Atlas genomics push Basecamp Research's Trillion Gene Atlas will bring together genomic data from millions of species to guide AI-powered design of new medicines.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.